Skip to main content

Table 1 Patient characteristics.

From: Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell Carcinoma: a prospective evaluation

  Baseline At time of switch to sorafenib
Number of patients 15 9
Median age (range) in yrs 58 (39-80)  
Gender, n   
   Male 11  
   Female 4  
ECOG Performance status, n   
   0-1 7  
   2 4  
   3 3  
   4 0  
Previous nephrectomy, n 14  
No. of disease sites, n   
   1 0  
   2 10  
   > = 3 45  
Metastatic sites, n   
   Lung 7  
   Lymph nodes 3  
   Bone 4  
   Peritoneum 4  
   Pancreas 1  
   Liver 5  
   CNS 1  
  1. GD, gemcitabine plus doxorubicin ECOG, Eastern Cooperative Oncology Croup; CNS, central nervous system